

Friday 23 May 2025

### ***Request under Freedom of Information Act 2000***

Thank you for your request for information which we received on Thursday 15 May 2025. I am pleased to confirm the following.

#### **Question One:**

**How many patients has your trust treated in the past six months (for any disease) with the following drugs:**

<b><i>Drug Name</i></b>	<b><i>Patient Number</i></b>
Aubagio (teriflunomide)	0
Avonex (interferon beta-1a)	0
Betaferon (interferon beta-1b)	0
Brabio (glatiramer acetate)	0
Copaxone (glatiramer acetate)	0
Extavia (beta interferon-1b)	0
Gilenya (fingolimod)	0
Kesimpta (ofatumumab)	0
Lemtrada (alemtuzumab)	0
Mavenclad (cladribine)	0
Mayzent (siponimod)	0
Ocrevus (ocrelizumab)	0
Plegridy (peginterferon beta-1a)	0
Ponvory (ponesimod)	0
Rebif (beta interferon-1a)	0
Tecfidera (dimethyl fumarate)	0
Tysabri (natalizumab)	0
Tysabri (natalizumab) Pre-filled syringes only	0
Vumerity (diroximel fumarate)	0
Zeposia (ozanimod)	0
Fingolimod generic	0
Tyruko (Natalizumab Biosimilar)	0

**Question Two:**

**How many patients has you trust treated with Rituximab for MS (Multiple Sclerosis) in the past six months?**

0 patients

**Question Three:**

**How many patients within your trust have a diagnosis of MS (Multiple Sclerosis)?**

Please see attached document.

If you are unhappy with the information received in response to this request, please address your complaint to the Patient Affairs Office at Milton Keynes Hospital NHS Foundation Trust, Standing Way, Eaglestone, Milton Keynes MK6 5LD. If, after exhausting our internal process, you are still unhappy with the information received, you may write to the Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF.

If you need any further assistance, please do not hesitate to contact us at the address above.

Yours sincerely

Freedom of Information Team Lead

For and on behalf of Milton Keynes Hospital NHS Foundation Trust

<p>Any re-use of this information will be subject to the 'Re-use of Public Sector Information Regulations' and best practice.</p>
---------------------------------------------------------------------------------------------------------------------------------------